Though more clinical trials are needed, preclinical evidence suggests that supplementation of NAD may be promising for preventing or lessening the risk of neurodegenerative diseases
NuRev Peptides does not make claims regarding outcomes, efficacy, or safety related to this product, and all offerings are presented as research peptides and laboratory-only materials
Ebadi M, Klangkalya B, Deupree JD
Immunol., 44, 878-888 OptiPrepApplication Sheet C44
Pen Dosage Chart Dosage & Protocols Variations Standard Research Protocol Dose: 0.1 0.3 mg (= 412 clicks) Duration: 2 4 weeks Frequency: Once daily, prior to rest phase Cycle Interval: 2 weeks off before repeating Goal / Description: Baseline protocol used in sleep architecture and circadian rhythm research models
References Compliance Notice This product is intended for laboratory research use only and is not approved for human or veterinary use.